Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.15
SLXP's Cash to Debt is ranked lower than
52% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. SLXP: 0.15 )
SLXP' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: 0.15

Equity to Asset 0.15
SLXP's Equity to Asset is ranked lower than
54% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SLXP: 0.15 )
SLXP' s 10-Year Equity to Asset Range
Min: 0.15   Max: 0.9
Current: 0.15

0.15
0.9
Interest Coverage 4.41
SLXP's Interest Coverage is ranked higher than
51% of the 491 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 97.33 vs. SLXP: 4.41 )
SLXP' s 10-Year Interest Coverage Range
Min: 3.1   Max: 9999.99
Current: 4.41

3.1
9999.99
F-Score: 3
Z-Score: 1.83
M-Score: -1.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 14.47
SLXP's Operating margin (%) is ranked higher than
83% of the 787 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.15 vs. SLXP: 14.47 )
SLXP' s 10-Year Operating margin (%) Range
Min: -511.93   Max: 29.1
Current: 14.47

-511.93
29.1
Net-margin (%) 4.67
SLXP's Net-margin (%) is ranked higher than
69% of the 787 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. SLXP: 4.67 )
SLXP' s 10-Year Net-margin (%) Range
Min: -475.24   Max: 16.17
Current: 4.67

-475.24
16.17
ROE (%) 8.46
SLXP's ROE (%) is ranked higher than
77% of the 796 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.47 vs. SLXP: 8.46 )
SLXP' s 10-Year ROE (%) Range
Min: -102   Max: 21.98
Current: 8.46

-102
21.98
ROA (%) 1.78
SLXP's ROA (%) is ranked higher than
66% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. SLXP: 1.78 )
SLXP' s 10-Year ROA (%) Range
Min: -77.4   Max: 10.41
Current: 1.78

-77.4
10.41
ROC (Joel Greenblatt) (%) 41.38
SLXP's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.76 vs. SLXP: 41.38 )
SLXP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7190.09   Max: 161.23
Current: 41.38

-7190.09
161.23
Revenue Growth (%) 34.20
SLXP's Revenue Growth (%) is ranked higher than
92% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SLXP: 34.20 )
SLXP' s 10-Year Revenue Growth (%) Range
Min: -2   Max: 112.5
Current: 34.2

-2
112.5
EBITDA Growth (%) 207.90
SLXP's EBITDA Growth (%) is ranked higher than
100% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. SLXP: 207.90 )
SLXP' s 10-Year EBITDA Growth (%) Range
Min: -28.2   Max: 207.9
Current: 207.9

-28.2
207.9
» SLXP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SLXP Guru Trades in Q3 2013

Paul Tudor Jones 8,400 sh (+95.35%)
Pioneer Investments 452,933 sh (+22.05%)
Vanguard Health Care Fund 2,147,945 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons 262,100 sh (-22.53%)
Steven Cohen 230,379 sh (-50.49%)
» More
Q4 2013

SLXP Guru Trades in Q4 2013

Jim Simons 268,519 sh (+2.45%)
Vanguard Health Care Fund 2,147,945 sh (unchged)
Pioneer Investments 410,439 sh (-9.38%)
Steven Cohen 97,861 sh (-57.52%)
Paul Tudor Jones 3,200 sh (-61.9%)
» More
Q1 2014

SLXP Guru Trades in Q1 2014

Andreas Halvorsen 1,551,766 sh (New)
Joel Greenblatt 307,445 sh (New)
Paul Tudor Jones 7,400 sh (+131.25%)
Pioneer Investments 450,432 sh (+9.74%)
Vanguard Health Care Fund 2,032,845 sh (-5.36%)
Jim Simons 90,134 sh (-66.43%)
Steven Cohen 7,830 sh (-92%)
» More
Q2 2014

SLXP Guru Trades in Q2 2014

Jim Simons 257,819 sh (+186.04%)
Andreas Halvorsen 2,889,303 sh (+86.19%)
Steven Cohen 527,800 sh (unchged)
Joel Greenblatt Sold Out
Pioneer Investments 417,255 sh (-7.37%)
Vanguard Health Care Fund 1,824,545 sh (-10.25%)
Paul Tudor Jones 1,800 sh (-75.68%)
» More
» Details

Insider Trades

Latest Guru Trades with SLXP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Andreas Halvorsen 2014-06-30 Add 86.19%0.74%$97.7 - $125.07 $ 140.4227%2889303
Joel Greenblatt 2014-06-30 Sold Out 0.48%$97.7 - $125.07 $ 140.4227%0
Andreas Halvorsen 2014-03-31 New Buy0.67%$88.8 - $114.64 $ 140.4238%1551766
Joel Greenblatt 2014-03-31 New Buy0.48%$88.8 - $114.64 $ 140.4238%307445
Joel Greenblatt 2013-09-30 Sold Out 0.36%$65.73 - $75.54 $ 140.42104%0
Joel Greenblatt 2013-06-30 New Buy0.36%$47.72 - $66.83 $ 140.42146%127495
Joel Greenblatt 2013-03-31 Sold Out 0.15%$40.472 - $51.37 $ 140.42193%0
Vanguard Health Care Fund 2013-03-31 Add 22.44%0.08%$40.472 - $51.37 $ 140.42193%2147945
NWQ Managers 2012-12-31 Sold Out 0.17%$37.97 - $42.9 $ 140.42244%0
Joel Greenblatt 2012-12-31 Add 75.81%0.06%$37.97 - $42.9 $ 140.42244%63399
Joel Greenblatt 2012-09-30 New Buy0.1%$41.92 - $55.65 $ 140.42196%36061
NWQ Managers 2012-03-31 Reduce -40.33%0.14%$45.72 - $53.75 $ 140.42204%656533
John Paulson 2011-09-30 Sold Out 0.2056%$26.18 - $40.9 $ 140.42325%0
NWQ Managers 2011-09-30 Add 198.07%0.18%$26.18 - $40.9 $ 140.42325%1320679
Vanguard Health Care Fund 2011-09-30 Add 55.43%0.09%$26.18 - $40.9 $ 140.42325%1554300
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 168.80
SLXP's P/E(ttm) is ranked higher than
60% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.30 vs. SLXP: 168.80 )
SLXP' s 10-Year P/E(ttm) Range
Min: 12.19   Max: 197.39
Current: 168.8

12.19
197.39
P/B 12.09
SLXP's P/B is ranked lower than
61% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. SLXP: 12.09 )
SLXP' s 10-Year P/B Range
Min: 1.01   Max: 14.15
Current: 12.09

1.01
14.15
P/S 7.59
SLXP's P/S is ranked higher than
53% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. SLXP: 7.59 )
SLXP' s 10-Year P/S Range
Min: 1.28   Max: 12.23
Current: 7.59

1.28
12.23
PFCF 59.25
SLXP's PFCF is ranked higher than
79% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SLXP: 59.25 )
SLXP' s 10-Year PFCF Range
Min: 5.08   Max: 371
Current: 59.25

5.08
371
EV-to-EBIT 62.08
SLXP's EV-to-EBIT is ranked higher than
70% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.86 vs. SLXP: 62.08 )
SLXP' s 10-Year EV-to-EBIT Range
Min: -1044.1   Max: 99.5
Current: 62.08

-1044.1
99.5
Shiller P/E 378.55
SLXP's Shiller P/E is ranked higher than
63% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 96.41 vs. SLXP: 378.55 )
SLXP' s 10-Year Shiller P/E Range
Min: 240.14   Max: 4937
Current: 378.55

240.14
4937
Current Ratio 1.52
SLXP's Current Ratio is ranked higher than
60% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. SLXP: 1.52 )
SLXP' s 10-Year Current Ratio Range
Min: 1.52   Max: 8.65
Current: 1.52

1.52
8.65
Quick Ratio 1.36
SLXP's Quick Ratio is ranked higher than
65% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. SLXP: 1.36 )
SLXP' s 10-Year Quick Ratio Range
Min: 1.36   Max: 7.92
Current: 1.36

1.36
7.92

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 7.23
SLXP's Price/DCF (Projected) is ranked higher than
76% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.00 vs. SLXP: 7.23 )
SLXP' s 10-Year Price/DCF (Projected) Range
Min: 2.38   Max: 76.06
Current: 7.23

2.38
76.06
Price/Median PS Value 1.51
SLXP's Price/Median PS Value is ranked higher than
66% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.25 vs. SLXP: 1.51 )
SLXP' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 3.88
Current: 1.51

0.29
3.88
Earnings Yield (Greenblatt) 1.60
SLXP's Earnings Yield (Greenblatt) is ranked higher than
51% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. SLXP: 1.60 )
SLXP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 9.7
Current: 1.6

1
9.7
Forward Rate of Return (Yacktman) 0.33
SLXP's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 683 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SLXP: 0.33 )
SLXP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8.5   Max: 1
Current: 0.33

-8.5
1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:XP2.Germany
Salix Pharmaceuticals, Ltd. incorporated in the state of Delaware. It is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases. The Company's 'search and development' efforts are designed to identify and acquire late-stage and/or marketed proprietary pharmaceutical products for the treatment of gastrointestinal disease that have an existing base of safety and efficacy data. Its products include APRISO, the first and only mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Another product, COLAZAL, treats mildly to moderately active ulcerative colitis, a form of inflammatory bowel disease. XIFAXAN is a nonsystemic antibiotic that treats travelers' diarrhea caused by non-invasive E. coli. PEPCID treats active duodenal ulcer, active benign gastric ulcer, and gastroesophageal reflux disease (GERD). OsmoPrep consists of a series of pills taken with the clear liquid. MoviPrep is a tolerable, low-volume liquid bowel prep with the effectiveness of high-volume prep. VISICOL, the precursor to OsmoPrep, this colonoscopy preparation also features a regimen of tablets taken with any clear liquid. Anusol-HC and PROCTOCORT provide soothing relief from anal itching, burning, and inflammation. AZASAN prevents rejection of kidney transplant and provides therapy for the management of severe active rheumatoid arthritis. Diuril treats high blood pressure and is an adjunctive therapy in edema associated with congestive heart failure, cirrhosis of the liver, corticosteroid and estrogen therapy, and kidney disease. The Company mainly sells its products to pharmaceutical wholesalers. The Company uses third party manufacturers to produce its products. The research, testing, manufacture, marketing and distribution of drug products are extensively regulated by governmental authorities in the United States and other countries.
» More Articles for SLXP

Headlines

Articles On GuruFocus.com
Bill Ackman and Valeant Could Sweeten Allergan Deal By $15 A Share Oct 10 2014 
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
Joel Greenblatt's Gotham Capital Top 5 New Stocks May 16 2014 
Weekly CFO Sells Highlight: FII, SLXP, CCK, VCI, WDC, STMP Dec 31 2012 
Weekly Guru Bargains Highlights: HMSY, FB, TSU, SLXP, ANR Oct 29 2012 
Value Shop Nuveen Investments Reports Second Quarter Portfolio Aug 19 2011 
Hedge Fund Giant John Paulson Reports Q2 Portfolio Aug 15 2011 
Salix Pharmaceuticals Ltd. (SLXP) President & CEO Carolyn J Logan sells 14,000 Shares Sep 23 2010 
Salix Pharmaceuticals Ltd. (SLXP) EVP Finance/CFO Adam C Derbyshire sells 5,000 Shares Dec 11 2009 
Salix Pharmaceuticals Ltd. (SLXP) EVP Finance/CFO Adam C Derbyshire sells 5,000 Shares Dec 02 2009 

More From Our Partners
Making Money With Charles Payne: 10/17/14 Oct 17 2014 - FOXBUSINESS

More From Other Websites
SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 23 2014
Salix Pharmaceuticals Announces 3Q2014 Financial Results Conference Call and Webcast Oct 23 2014
Salix’s TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg... Oct 21 2014
Salix’s TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg... Oct 21 2014
SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 17 2014
Salix Pharmaceuticals Outlines Data Presentations at American College of Gastroenterology 2014... Oct 17 2014
Salix Pharmaceuticals Outlines Data Presentations at American College of Gastroenterology 2014... Oct 17 2014
AbbVie sours on $55B Shire deal after tax changes Oct 16 2014
AbbVie Board To Shareholders: Vote No On Shire Buy Oct 16 2014
Shire Falls, AbbVie Questioned On Buyout Backtrack Oct 15 2014
[$$] Italy's Cosmo Plans Relocation to Luxembourg Oct 15 2014
Cosmo Plans Management Move in Search of Irish Corporate Charm Oct 15 2014
Pharming and Swedish Orphan Biovitrum Amend and Extend Ruconest Distribution Agreement Oct 12 2014
Inversion Vitriol Vs. Drug Consolidation Oct 10 2014
Allergan Raises Outlook amidst Valeant Takeover Attempts Oct 10 2014
Salix's Rectal Foam Uceris Receives Final FDA Approval Oct 09 2014
Allergan Steeply Raises Guidance, Taunts Valeant Oct 09 2014
SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 08 2014
Allergan & Valeant & Actavis & Salix: Can This Love Quadrilateral Work? Oct 08 2014
FDA Approves UCERIS® (Budesonide) 2mg Rectal Foam for the Induction of Remission of... Oct 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK